Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-aventis has entered into a three-year cooperation agreement with its ophthalmology division, Fovea Pharmaceuticals and Vision Institute to conduct a research on ocular diseases its prevention and measures.
Subscribe to our email newsletter
The tie up allows Sanofi-aventis to develop a platform for ophthalmology so as to introduce more solutions for patients where unmet therapeutic needs remain, Pharmabiz reported.
Under the contract, Vision Institute will give priority access for its technological platforms to Sanofi-aventis for organizing research activities and to support research and collaboration projects for vascular biology, regeneration of the optical nerve, inflammation and gene therapy in various eye tissues.
Pharmabiz has quoted Sanofi-aventis CEO Christopher Viehbacher as saying that the collaboration will encourage the sharing of technical expertise and know-how with the objective to deliver innovative therapies for people with visual impairment and supports their ambition to build a global offer in ophthalmology for patients.